Helicobacter pylori is a spiral-shaped gram-negative bacterium involved in the development of gastritis, duodenal and gastric ulcers, and gastric cancer.
Infection is strongly associated with the development of gastric epithelial and lymphoid malignancies.
Acute infection is mostly asymptomatic and is acquired through human-to-human contact via gastro-oral and fecal-oral routes.
Adaptability in gastric conditions and production of urease allow it to colonize the stomach.
Consuming cranberry juice twice daily for 8 weeks can help suppress Helicobacter (H.) pylori infection among Chinese adults, suggests a randomized study — thus opening the door to using cranberry juice as a complementary approach to H. pylori management.
A 7-day course of vonoprazan and low-dose amoxicillin dual (VA-dual) therapy proves useful in the first-line treatment of Helicobacter pylori infection, especially in regions with high clarithromycin resistance, yielding an acceptable eradication efficacy that is similar to that achieved with vonoprazan-based triple (VAC-triple) therapy, according to the results of an open-label trial.
A 10-day or 14-day sequential therapy strategy is more cost-effective than a conventional triple therapy in the management of patients with Helicobacter pylori infection, in addition to being more effective in terms of eradication of infection, as reported in a study from Egypt.
Helicobacter pylori-eradication therapy in patients with nonalcoholic fatty liver disease (NAFLD) leads to greater improvement in homeostasis model assessment-insulin resistance but exerts comparable effects on hepatic steatosis and liver enzymes as compared with diet and exercise alone, a study has shown.
Individuals with type 2 diabetes mellitus (T2D) may be at risk of developing gastric cancer even after receiving Helicobacter pylori (H. pylori) eradication therapy, demonstrated a study from Hong Kong.